However, the use of ZEB1/AR pathways as a prognostic marker and therapeutic target in GC patients warrants further investigation to explore the exact mechanism of interaction between them besides assessment of anti-AR therapy in GC patients via larger cohort studies and randomized clinical trials. The gene discussed is ZEB1; the disease is gastric cancer.